Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
The objective of this study was to compare the quality of life in patients with endometriosis undergoing treatment with progestins, OCPs, and GnRH agonists.
Endometriosis contributes to 5-21% of hospital admissions for pelvic pain. While hormonal therapies are pivotal in managing endometriosis-related pain, no single hormonal treatment suits all patients. We aimed to assess …
Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …
Hormonal Birth Control vs. GnRH Agonists for Endometriosis HealthCentral
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight The Malaysian Reserve
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight PR Newswire UK
GnRH Receptor Antagonists Market Poised for Significant openPR.com
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …